Skip to content

EBITDA at other companies

PTH
Pelthos Therapeutics Inc.PTHS
-$11.59M-532%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$12.48M-6.7%
RFL
Rafael Holdings, Inc.RFL
-$6.82M-16.6%
Opko Health logo
Opko HealthOPK
-$28.82M+34.0%
Baxter International logo
Baxter InternationalBAX
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$9.1M-22.0%
Gross profit$7.2M-30.0%
Operating income-$3.1M-342%
Net income-$3.3M-362%
EPS (diluted)-$0.22-375%

Balance sheet

See full
Cash & equivalents$11.0M-27.1%
Total debt$4.8M-7.1%
Total equity$21.6M-24.5%
Total assets$71.0M+1.5%

Cash flow

See full
Operating cash flow$387.0K-90.1%
CapEx--100%
Free cash flow$387.0K-89.9%

Valuation

See full
Market cap$97.09M+142%
Enterprise value$90.91M+212%
P/S2.3×+1.4×

Profitability

See full
Gross margin82.9%-1.4pp
Operating margin-17.2%-125pp
Net margin-17.6%-103pp
FCF margin3.3%

Returns & leverage

See full
Return on equity-29.4%-86.3pp
Debt / equity0.2×0.0×
Current ratio-0.3×

Where this comes from

Calculated from Cumberland Pharmaceuticals’s reported figures.

$3.1Mebit+
$1.3MDepreciation Depletion & Amortization
=-$1.85M

The official record: Cumberland Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cumberland Pharmaceuticals's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cumberland Pharmaceuticals's EBITDA?
Cumberland Pharmaceuticals (CPIX) reported EBITDA of -$1.85M in Q1 2026.
How has Cumberland Pharmaceuticals's EBITDA changed year-over-year?
Cumberland Pharmaceuticals's EBITDA decreased by 179.7% year-over-year, from $2.32M to -$1.85M.
What is the long-term trend for Cumberland Pharmaceuticals's EBITDA?
Over 4 years (2021 to 2025), Cumberland Pharmaceuticals's EBITDA has grown at a -18.5% compound annual growth rate (CAGR), from -$3.07M to $1.35M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.